Back to Report Store Home

Antibacterial Therapies Drug Development Pipeline Review, 2017

  • Published: Mar-2017
  • Report Code: GBIHC004IDB
  • Report Format: pdf

Description

List of Figures

Number of Products under Development for Tuberculosis

Number of Products under Development for Tuberculosis – Comparative Analysis

Number of Products under Development for Community Acquired Pneumonia

Number of Products under Development for Hospital Acquired Pneumonia (HAP)

Number of Products under Development for Hospital Acquired Pneumonia (HAP) – Comparative Analysis

Number of Products under Development for Ventilator Associated Pneumonia (VAP)

Number of Products under Development for Ventilator Associated Pneumonia (VAP) – Comparative Analysis

Number of Products under Development for Pseudomonas aeruginosa Infections

Number of Products under Development for Pseudomonas aeruginosa Infections – Comparative Analysis

Number of Products under Development for Klebsiella pneumoniae Infections

Number of Products under Development for Klebsiella pneumoniae Infections – Comparative Analysis

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Comparative Analysis

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections – Comparative Analysis

Number of Products under Development by Companies, Tuberculosis

Number of Products under Development by Companies, Community Acquired Pneumonia

Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP)

Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP)

Number of Products under Development by Companies, Pseudomonas aeruginosa Infections

Number of Products under Development by Companies, Klebsiella pneumoniae Infections

Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products under Investigation by Universities/Institutes, Tuberculosis

Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections

Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections

Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Comparative Analysis by Late Stage Development, Tuberculosis

Comparative Analysis by Clinical Stage Development, Tuberculosis

Comparative Analysis by Early Stage Products, Tuberculosis

Comparative Analysis by Late Stage Development, Community Acquired Pneumonia

Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia

Comparative Analysis by Early Stage Products, Community Acquired Pneumonia

Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP)

Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP)

Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP)

Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP)

Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP)

Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP)

Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections

Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections

Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections

Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections

Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections

Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Assessment by Monotherapy Products, Tuberculosis

Assessment by Combination Products, Tuberculosis

Number of Products by Top 10 Targets, Tuberculosis

Number of Products by Stage and Top 10 Targets, Tuberculosis

Number of Products by Top 10 Mechanism of Actions, Tuberculosis

Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis

Number of Products by Top 10 Routes of Administration, Tuberculosis

Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis

Number of Products by Top 10 Molecule Types, Tuberculosis

Number of Products by Stage and Top 10 Molecule Types, Tuberculosis

Assessment by Monotherapy Products, Community Acquired Pneumonia

Number of Products by Targets, Community Acquired Pneumonia

Number of Products by Stage and Targets, Community Acquired Pneumonia

Number of Products by Mechanism of Actions, Community Acquired Pneumonia

Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia

Number of Products by Routes of Administration, Community Acquired Pneumonia

Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia

Number of Products by Molecule Types, Community Acquired Pneumonia

Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia

Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP)

Assessment by Combination Products, Hospital Acquired Pneumonia (HAP)

Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP)

Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP)

Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP)

Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP)

Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP)

Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP)

Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP)

Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP)

Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP)

Assessment by Combination Products, Ventilator Associated Pneumonia (VAP)

Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP)

Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP)

Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP)

Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP)

Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP)

Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP)

Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP)

Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP)

Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections

Assessment by Combination Products, Pseudomonas aeruginosa Infections

Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections

Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections

Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections

Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections

Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections

Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections

Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections

Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections

Assessment by Monotherapy Products, Klebsiella pneumoniae Infections

Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections

Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections

Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections

Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections

Number of Products by Routes of Administration, Klebsiella pneumoniae Infections

Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections

Number of Products by Molecule Types, Klebsiella pneumoniae Infections

Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections

Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards